Vietnam is emerging as one of Southeast Asia's most promising biotechnology markets, with growing investment in genomics, molecular diagnostics and precision medicine driving increasing demand for oligonucleotide synthesis technologies.
Although no standalone valuation has been published for Vietnam's oligonucleotide synthesis market, industry analysis estimates the sector is currently worth US$28–38 million in 2025 and is projected to reach US$45–60 million by 2030.
Oligonucleotide synthesis is the chemical production of short DNA and RNA sequences that underpin many of today's most important life science applications. These synthetic nucleic acids are essential for molecular diagnostics, PCR testing, DNA sequencing, CRISPR gene editing, cell and gene therapy research and the development of RNA-based therapeutics.
The market includes:
- DNA and RNA oligonucleotide synthesis
- PCR primers
- Sequencing primers
- Molecular diagnostic probes
- CRISPR guide RNAs
- Antisense oligonucleotides (ASOs)
- Small interfering RNA (siRNA)
- Aptamers
- Reagents and consumables
- Automated synthesis instruments
- Contract synthesis services
Several long-term trends are driving growth across Vietnam:
- Expansion of molecular diagnostics and genetic testing.
- Increasing investment in biotechnology research.
- Growth in pharmaceutical and biopharmaceutical manufacturing.
- Rising adoption of precision medicine.
- Expansion of genomic sequencing programmes.
- Development of cell and gene therapies.
- Increased collaboration between academia, hospitals and industry.
Vietnam's broader life sciences sector continues to strengthen. According to IMARC Group, the country's Life Science Tools Market reached US$712.2 million in 2025 and is forecast to grow to US$1.412 billion by 2034, supported by increasing demand for advanced research tools, drug discovery technologies and molecular biology platforms. Technologies including PCR, sequencing, flow cytometry and genomics—all major users of synthetic oligonucleotides—are identified as key growth areas.
Demand is also being fuelled by advances in molecular diagnostics. IMARC Group estimates Vietnam's Molecular Diagnostics Market reached US$108.5 million in 2025 and is projected to grow to US$175.6 million by 2034. Oligonucleotides are essential components of PCR assays, DNA sequencing workflows, hybridisation technologies and other molecular diagnostic applications that continue to expand across hospitals and research laboratories.
Globally, oligonucleotide synthesis has become one of the fastest-growing areas of biotechnology. According to IMARC Group, the Global Oligonucleotide Synthesis Market reached US$3.7 billion in 2025 and is forecast to expand to US$8.7 billion by 2034. Growth is being driven by increasing demand for personalised medicine, advances in genomics, wider use of CRISPR gene editing, and expanding applications for antisense oligonucleotides and RNA-based therapeutics. Pharmaceutical and biotechnology companies remain the largest end users of synthetic oligonucleotides.
Technology continues to reshape the industry. Modern high-throughput synthesis platforms are producing longer, higher-purity oligonucleotides with greater efficiency than ever before. Automation, advanced phosphoramidite chemistry, AI-assisted sequence optimisation and improved purification technologies are reducing production costs while enabling increasingly complex applications in diagnostics, synthetic biology and therapeutic development.
Vietnam is also benefiting from increased investment in biomedical research, vaccine development and precision medicine. Universities, government research institutes and biotechnology companies are expanding capabilities in genomics and molecular biology, creating new opportunities for suppliers of oligonucleotide synthesis technologies and specialist laboratory services.
Leading companies operating in the global market include Thermo Fisher Scientific, Integrated DNA Technologies (Danaher), Eurofins Genomics, GenScript, Agilent Technologies, LGC Biosearch Technologies, Eurogentec (Kaneka), Bio-Synthesis, Nitto Denko Avecia and Merck KGaA, all of which continue to expand their portfolios of synthesis products, reagents, equipment and custom manufacturing services.
As Vietnam continues to strengthen its biotechnology ecosystem and invest in advanced life sciences, oligonucleotide synthesis will become an increasingly strategic enabling technology for research, diagnostics and therapeutic innovation. For manufacturers of synthesis equipment, reagents, consumables, contract synthesis services and genomics technologies, Vietnam represents one of Southeast Asia's most attractive long-term growth opportunities.